Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TG TherapeuticsFRA:NKB2 +0.72%78 Debt-to-Equity is 1.25 as of Jun. 2026, which is 198% above its 10-year median of 0.42. GuruFocus rates FRA:NKB2 with a GF Score™ of 78/100 and a GF Value™ of €50.93 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 965 Biotechnology companies, TG Therapeutics ranks worse than 89.64% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TG Therapeutics's Debt-to-Equity or its related term are showing as below:
FRA:NKB2'
s Debt-to-Equity Range Over the Past 10 Years
Min: -30.28 Med: 0.42 Max: 3.94
Current: 1.25
During the past 13 years, the highest Debt-to-Equity Ratio of TG Therapeutics was 3.94. The lowest was -30.28. And the median was 0.42.
FRA:NKB2's Debt-to-Equity is ranked worse than 89.64% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs FRA:NKB2: 1.25
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TG Therapeutics Debt-to-Equity Related Terms
TG Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TG Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NKB2 vs PTGX, CRNX, SYRE: Debt-to-Equity Comparison
For the Biotechnology subindustry, TG Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics (FRA:NKB2) has a Debt-to-Equity of 1.25 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TG Therapeutics and its competitors. This is 198% above median its historical median of 0.42. According to the industry distribution chart, TG Therapeutics ranks #865 out of 965 companies in the Biotechnology industry, placing it in the top 89.6%.
Is TG Therapeutics' Debt-to-Equity too high?
TG Therapeutics' current Debt-to-Equity of 1.25 is 198% above median its 10-year median of 0.42. The Biotechnology industry median Debt-to-Equity is 0.15. TG Therapeutics' value of 1.25 is 733.3% above this industry median. Based on the distribution chart, TG Therapeutics ranks #865 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TG Therapeutics has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Debt-to-Equity compare to PTGX and CRNX?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #865 out of 965 companies for Debt-to-Equity. This places TG Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.15. TG Therapeutics' value of 1.25 is 733.3% above this benchmark. While the company's 10-year median is 0.42 vs. the industry median of 0.15, TG Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TG Therapeutics's current Debt-to-Equity of 1.25 is 733.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TG Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TG Therapeutics's current Debt-to-Equity is 1.25, which is 198% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Modestly Undervalued. The stock's GF Value™ is €50.93, compared to a current price of €42.00 — trading 17.5% below its estimated fair value. The current Debt-to-Equity is 1.25, which is 198% above median its 10-year median of 0.42 and 733.3% above the Biotechnology industry median of 0.15. TG Therapeutics' overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Debt-to-Equity is 1.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued.
The current stock price of €42.00 is trading 17.5% below its estimated GF Value™ of €50.93.
GuruFocus considers TG Therapeutics to be Modestly Undervalued.
Key valuation signals for FRA:NKB2:
Debt-to-Equity: 1.25 (198% above median its 10-year median of 0.42)
GF Value™: €50.93 vs. price of €42.00 (17.5% below fair value)
Industry Position: 733.3% above the Biotechnology median (#865 of 965)
No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
78GF Score
Get the complete analysis for FRA:NKB2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
